GLP-1/Weight Loss

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

A Canadian company's sublingual tablet could replace injections for popular peptides, just as the FDA considers expanding access for millions of users.

With Ozempic at generic prices and a new free-to-start model, Felix Health is making high-demand weight-loss drugs more accessible than ever for Canadians.

A new telehealth platform offers popular weight loss drugs for $149/month, but there's a catch: they aren't FDA-approved. Here's what you need to know.

With backing from GV and Dexcom, Signos is using AI and OTC glucose monitors to offer a new path for sustainable weight management beyond GLP-1 drugs.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Wellness brand Le-Vel is launching a telehealth service for prescription peptides, blurring the lines between direct sales and mainstream medicine.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

A new analysis reveals most insured Americans can't access obesity drugs, even with coverage, due to restrictive insurance hurdles.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A $182,500 seizure in Quebec is just the tip of the iceberg, revealing a nationwide struggle against high-tech smuggling, drones, and prison violence.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Ozari Health launches a nationwide service for affordable compounded semaglutide, navigating a complex and increasingly regulated market for GLP-1 drugs.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

With 12% weight loss in a pivotal trial, Vincentage Pharma's VCT220 pill is set to challenge injectables and reshape China's obesity drug market.